Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) have been assigned a consensus recommendation of “Hold” from the thirteen analysts that are covering the firm, Marketbeat.com reports. Three analysts have rated the stock with a sell rating, five have issued a hold rating and four have issued a buy rating on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $41.11.
MYGN has been the subject of several analyst reports. Barclays boosted their target price on Myriad Genetics from $35.00 to $38.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 22nd. Zacks Investment Research lowered Myriad Genetics from a “buy” rating to a “hold” rating in a report on Monday, October 29th. Deutsche Bank boosted their target price on Myriad Genetics from $37.00 to $43.00 and gave the stock a “hold” rating in a report on Monday, November 5th. Piper Jaffray Companies upgraded Myriad Genetics from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $38.00 to $53.00 in a report on Wednesday, October 10th. Finally, TheStreet lowered Myriad Genetics from a “b” rating to a “c” rating in a report on Thursday, November 8th.
Several hedge funds have recently modified their holdings of the company. BlackRock Inc. lifted its holdings in shares of Myriad Genetics by 3.5% during the third quarter. BlackRock Inc. now owns 11,466,610 shares of the company’s stock worth $527,464,000 after buying an additional 383,089 shares during the last quarter. Baillie Gifford & Co. lifted its holdings in shares of Myriad Genetics by 1.0% during the third quarter. Baillie Gifford & Co. now owns 9,547,193 shares of the company’s stock worth $439,171,000 after buying an additional 92,008 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Myriad Genetics by 4.4% during the third quarter. Vanguard Group Inc. now owns 8,656,933 shares of the company’s stock worth $398,219,000 after buying an additional 365,697 shares during the last quarter. Frontier Capital Management Co. LLC lifted its holdings in shares of Myriad Genetics by 8.4% during the third quarter. Frontier Capital Management Co. LLC now owns 2,575,754 shares of the company’s stock worth $118,485,000 after buying an additional 198,819 shares during the last quarter. Finally, Acadian Asset Management LLC lifted its holdings in shares of Myriad Genetics by 2.6% during the third quarter. Acadian Asset Management LLC now owns 2,387,166 shares of the company’s stock worth $109,812,000 after buying an additional 59,446 shares during the last quarter. Institutional investors own 99.80% of the company’s stock.
Shares of NASDAQ MYGN traded down $0.62 during trading hours on Monday, hitting $31.51. The stock had a trading volume of 973,445 shares, compared to its average volume of 886,170. The stock has a market cap of $2.40 billion, a price-to-earnings ratio of 26.26, a PEG ratio of 1.86 and a beta of 0.36. Myriad Genetics has a 52 week low of $27.27 and a 52 week high of $50.44. The company has a debt-to-equity ratio of 0.23, a quick ratio of 2.83 and a current ratio of 3.17.
Myriad Genetics (NASDAQ:MYGN) last announced its quarterly earnings results on Tuesday, November 6th. The company reported $0.43 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.30 by $0.13. The business had revenue of $202.30 million during the quarter, compared to analysts’ expectations of $203.20 million. Myriad Genetics had a return on equity of 10.07% and a net margin of 7.07%. The firm’s quarterly revenue was up 13.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.26 EPS. On average, analysts predict that Myriad Genetics will post 1.5 EPS for the current year.
About Myriad Genetics
Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.
Featured Article: Stock Symbols and CUSIP Explained
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.